Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Short term Debt (2016 - 2025)

Historic Short term Debt for Abvc Biopharma (ABVC) over the last 12 years, with Q3 2025 value amounting to $809103.0.

  • Abvc Biopharma's Short term Debt fell 972.35% to $809103.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $809103.0, marking a year-over-year decrease of 972.35%. This contributed to the annual value of $840252.0 for FY2024, which is 656.08% down from last year.
  • As of Q3 2025, Abvc Biopharma's Short term Debt stood at $809103.0, which was down 972.35% from $871951.0 recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Short term Debt registered a high of $1.9 million during Q4 2022, and its lowest value of $298269.0 during Q3 2021.
  • In the last 5 years, Abvc Biopharma's Short term Debt had a median value of $847000.0 in 2024 and averaged $875073.0.
  • As far as peak fluctuations go, Abvc Biopharma's Short term Debt crashed by 8244.19% in 2021, and later skyrocketed by 38135.09% in 2022.
  • Quarter analysis of 5 years shows Abvc Biopharma's Short term Debt stood at $393424.0 in 2021, then skyrocketed by 381.35% to $1.9 million in 2022, then crashed by 52.51% to $899250.0 in 2023, then fell by 6.56% to $840252.0 in 2024, then fell by 3.71% to $809103.0 in 2025.
  • Its last three reported values are $809103.0 in Q3 2025, $871951.0 for Q2 2025, and $801407.0 during Q1 2025.